ADVM — Adverum Biotechnologies Cashflow Statement
0.000.00%
Last trade - 00:00- $169.58m
- -$23.74m
- $3.60m
- 16
- 35
- 51
- 26
Annual cashflow statement for Adverum Biotechnologies, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -64.5 | -118 | -146 | -155 | -117 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 8.68 | 21.3 | 29 | 20 | 15.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 5.06 | 12.7 | 4.06 | 19.9 | 4.71 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -49.2 | -79.3 | -108 | -108 | -90.9 |
| Capital Expenditures | -19.2 | -11.8 | -15.1 | -11.8 | -0.808 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -48.8 | -268 | 93.8 | 154 | 97.7 |
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -68.1 | -280 | 78.7 | 142 | 96.9 |
| Financing Cash Flow Items | -1.47 | -2.04 | 0 | — | -0.42 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 28.2 | 356 | 2.4 | 0.607 | 0.069 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -89.1 | -3.47 | -26.7 | 34.2 | 6.04 |